Recombinant Bovine/human Parainfluenza Virus Type 3 (B/HPIV3) Expressing the Respiratory Syncytial Virus (RSV) G and F Proteins Can Be Used to Achieve Simultaneous Mucosal Immunization Against RSV and HPIV3

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2001 Apr 20

PMID 11312329

Citations 46

Authors

A C Schmidt

J M McAuliffe

B R Murphy

P L Collins

Affiliations

Soon will be listed here.

Abstract

Recombinant bovine/human parainfluenza virus type 3 (rB/HPIV3), a recombinant bovine PIV3 (rBPIV3) in which the F and HN genes were replaced with their HPIV3 counterparts, was used to express the major protective antigens of respiratory syncytial virus (RSV) in order to create a bivalent mucosal vaccine against RSV and HPIV3. The attenuation of rB/HPIV3 is provided by the host range restriction of the BPIV3 backbone in primates. RSV G and F open reading frames (ORFs) were placed under the control of PIV3 transcription signals and inserted individually into the rB/HPIV3 genome in the promoter-proximal position preceding the nucleocapsid protein gene. The recombinant PIV3 expressing the RSV G ORF (rB/HPIV3-G1) was not restricted in its replication in vitro, whereas the virus expressing the RSV F ORF (rB/HPIV3-F1) was eightfold restricted compared to its rB/HPIV3 parent. Both viruses replicated efficiently in the respiratory tract of hamsters, and each induced RSV serum antibody titers similar to those induced by RSV infection and anti-HPIV3 titers similar to those induced by HPIV3 infection. Immunization of hamsters with rB/HPIV3-G1, rB/HPIV3-F1, or a combination of both viruses resulted in a high level of resistance to challenge with RSV or HPIV3 28 days later. These results describe a vaccine strategy that obviates the technical challenges associated with a live attenuated RSV vaccine, providing, against the two leading viral agents of pediatric respiratory tract disease, a bivalent vaccine whose attenuation phenotype is based on the extensive host range sequence differences of BPIV3.

Citing Articles

Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.

Henriquez R, Munoz-Barroso I Heliyon. 2024; 10(15):e34927.

PMID: 39144987 PMC: 11320483. DOI: 10.1016/j.heliyon.2024.e34927.

Mucosal bivalent live attenuated vaccine protects against human metapneumovirus and respiratory syncytial virus in mice.

Ogonczyk-Makowska D, Brun P, Vacher C, Chupin C, Droillard C, Carbonneau J NPJ Vaccines. 2024; 9(1):111.

PMID: 38898106 PMC: 11187144. DOI: 10.1038/s41541-024-00899-9.

Immunoinformatics-aided rational design of multiepitope-based peptide vaccine (MEBV) targeting human parainfluenza virus 3 (HPIV-3) stable proteins.

Hossen M, Hasan M, Haque M, Arian T, Halder S, Jasim Uddin M J Genet Eng Biotechnol. 2023; 21(1):162.

PMID: 38055114 PMC: 10700276. DOI: 10.1186/s43141-023-00623-5.

Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters.

Liu X, Park H, Matsuoka Y, Santos C, Yang L, Luongo C PLoS Pathog. 2023; 19(6):e1011057.

PMID: 37352333 PMC: 10325082. DOI: 10.1371/journal.ppat.1011057.

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.

Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y Signal Transduct Target Ther. 2023; 8(1):149.

PMID: 37029123 PMC: 10081433. DOI: 10.1038/s41392-023-01408-5.

References

Collins P, Olmsted R, Spriggs M, Johnson P . Gene overlap and site-specific attenuation of transcription of the viral polymerase L gene of human respiratory syncytial virus. Proc Natl Acad Sci U S A. 1987; 84(15):5134-8. PMC: 298808. DOI: 10.1073/pnas.84.15.5134. View

Makhene M, Mrukowicz J, Wright P, Hoshino Y, Midthun K, SPERBER E . Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine. 1999; 17(20-21):2715-25. DOI: 10.1016/s0264-410x(98)00497-6. View

Murphy B, Olmsted R, Collins P, Chanock R, Prince G . Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J Virol. 1988; 62(10):3907-10. PMC: 253544. DOI: 10.1128/JVI.62.10.3907-3910.1988. View

Murphy B, Walsh E . Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol. 1988; 26(8):1595-7. PMC: 266671. DOI: 10.1128/jcm.26.8.1595-1597.1988. View

Murphy B, Prince G, Collins P, Van Wyke Coelingh K, Olmsted R, Spriggs M . Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res. 1988; 11(1):1-15. DOI: 10.1016/0168-1702(88)90063-9. View

Beeler J, Van Wyke Coelingh K . Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol. 1989; 63(7):2941-50. PMC: 250848. DOI: 10.1128/JVI.63.7.2941-2950.1989. View

Murphy B, Sotnikov A, Lawrence L, Banks S, Prince G . Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine. 1990; 8(5):497-502. DOI: 10.1016/0264-410x(90)90253-i. View

Clements M, Belshe R, King J, Newman F, Westblom T, Tierney E . Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol. 1991; 29(6):1175-82. PMC: 269965. DOI: 10.1128/jcm.29.6.1175-1182.1991. View

Connors M, Kulkarni A, Collins P, Firestone C, Holmes K, Morse 3rd H . Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by.... J Virol. 1992; 66(2):1277-81. PMC: 240842. DOI: 10.1128/JVI.66.2.1277-1281.1992. View

10.

Clements M, Subbarao E, Fries L, Karron R, London W, Murphy B . Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J Clin Microbiol. 1992; 30(3):655-62. PMC: 265127. DOI: 10.1128/jcm.30.3.655-662.1992. View

11.

Connors M, Collins P, Firestone C, Sotnikov A, Waitze A, Davis A . Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV. Vaccine. 1992; 10(7):475-84. DOI: 10.1016/0264-410x(92)90397-3. View

12.

Hall S, Stokes A, Tierney E, London W, Belshe R, Newman F . Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 1992; 22(3):173-84. DOI: 10.1016/0168-1702(92)90049-f. View

13.

Subbarao E, Perkins M, Treanor J, Murphy B . The attenuation phenotype conferred by the M gene of the influenza A/Ann Arbor/6/60 cold-adapted virus (H2N2) on the A/Korea/82 (H3N2) reassortant virus results from a gene constellation effect. Virus Res. 1992; 25(1-2):37-50. DOI: 10.1016/0168-1702(92)90098-t. View

14.

Kapikian A, Vesikari T, Ruuska T, Madore H, Christy C, Dolin R . An update on the "Jennerian" and modified "Jennerian" approach to vaccination of infants and young children against rotavirus diarrhea. Adv Exp Med Biol. 1992; 327:59-69. DOI: 10.1007/978-1-4615-3410-5_8. View

15.

Calain P, Roux L . The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol. 1993; 67(8):4822-30. PMC: 237869. DOI: 10.1128/JVI.67.8.4822-4830.1993. View

16.

Alwan W, Kozlowska W, Openshaw P . Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med. 1994; 179(1):81-9. PMC: 2191312. DOI: 10.1084/jem.179.1.81. View

17.

Crowe Jr J, Collins P, London W, Chanock R, Murphy B . A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine. 1993; 11(14):1395-404. DOI: 10.1016/0264-410x(93)90168-w. View

18.

Kulkarni A, Collins P, Bacik I, Yewdell J, Bennink J, Crowe Jr J . Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J Virol. 1995; 69(2):1261-4. PMC: 188700. DOI: 10.1128/JVI.69.2.1261-1264.1995. View

19.

Karron R, Wright P, Hall S, Makhene M, Thompson J, Burns B . A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis. 1995; 171(5):1107-14. DOI: 10.1093/infdis/171.5.1107. View

20.

Crowe Jr J . Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine. 1995; 13(4):415-21. DOI: 10.1016/0264-410x(95)98266-d. View